Keyphrases
Pediatric Patients
100%
Filgrastim
100%
Etoposide
100%
Ifosfamide
100%
Refractory Solid Tumors
100%
Phase I Clinical Trial
100%
Oxaliplatin
100%
Dose-limiting Toxicity
66%
Maximum Tolerated Dose
66%
Neutropenia
50%
Dose Level
33%
Carboplatin
16%
Dose Escalation
16%
Partial Response
16%
Neurotoxicity
16%
Cisplatin
16%
Nephrotoxicity
16%
Stable Disease
16%
Combination Regimen
16%
Pegfilgrastim
16%
Toxicity Profile
16%
Ototoxicity
16%
Initial Dose
16%
Pharmacology, Toxicology and Pharmaceutical Science
Solid Malignant Neoplasm
100%
Clinical Trial
100%
Filgrastim
100%
Ifosfamide
100%
Etoposide
100%
Oxaliplatin
100%
Maximum Tolerated Dose
66%
Neutropenia
50%
Carboplatin
16%
Isoprenaline
16%
Neurotoxicity
16%
Cisplatin
16%
Nephrotoxicity
16%
Pegfilgrastim
16%
Ototoxicity
16%
Diseases
16%
Immunology and Microbiology
Filgrastim
100%
Pegfilgrastim
16%